- Home
- BEAM vs NWBI Comparison
BEAM vs NWBI Comparison
Compare BEAM & NWBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEAM
- NWBI
- Stock Information
- Founded
- BEAM 2017
- NWBI 1896
- Country
- BEAM United States
- NWBI United States
- Employees
- BEAM N/A
- NWBI N/A
- Industry
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- NWBI Major Banks
- Sector
- BEAM Health Care
- NWBI Finance
- Exchange
- BEAM Nasdaq
- NWBI Nasdaq
- Market Cap
- BEAM 1.6B
- NWBI 1.6B
- IPO Year
- BEAM 2020
- NWBI N/A
- Fundamental
- Price
- BEAM $20.01
- NWBI $13.49
- Analyst Decision
- BEAM Strong Buy
- NWBI Hold
- Analyst Count
- BEAM 11
- NWBI 1
- Target Price
- BEAM $48.90
- NWBI $15.00
- AVG Volume (30 Days)
- BEAM 2.0M
- NWBI 641.7K
- Earning Date
- BEAM 08-05-2025
- NWBI 07-22-2025
- Dividend Yield
- BEAM N/A
- NWBI 5.93%
- EPS Growth
- BEAM N/A
- NWBI N/A
- EPS
- BEAM N/A
- NWBI 0.90
- Revenue
- BEAM $63,578,000.00
- NWBI $518,578,999.00
- Revenue This Year
- BEAM N/A
- NWBI $7.29
- Revenue Next Year
- BEAM $8.82
- NWBI $11.29
- P/E Ratio
- BEAM N/A
- NWBI $14.99
- Revenue Growth
- BEAM N/A
- NWBI N/A
- 52 Week Low
- BEAM $13.53
- NWBI $10.75
- 52 Week High
- BEAM $35.25
- NWBI $15.42
- Technical
- Relative Strength Index (RSI)
- BEAM 68.31
- NWBI 73.34
- Support Level
- BEAM $16.59
- NWBI $12.71
- Resistance Level
- BEAM $17.38
- NWBI $13.00
- Average True Range (ATR)
- BEAM 1.10
- NWBI 0.28
- MACD
- BEAM 0.35
- NWBI 0.11
- Stochastic Oscillator
- BEAM 89.70
- NWBI 94.30
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
About NWBI Northwest Bancshares Inc.
Northwest Bancshares Inc is a stockholding company for Northwest Bank. Northwest Bank is a stock savings bank and a community-oriented financial institution offering personal and commercial banking business solutions, investment management, trust services, and insurance products. It also offers consumer finance loans through a wholly-owned subsidiary. The bank's loan portfolio segment consists of personal banking and business banking loans. Personal banking includes residential mortgages, home equity loans, and other consumer loans. Business banking loans consist of commercial real estate loans and commercial loans. Net interest income is the company's primary contributor to revenue.